Alembic Pharma gets USFDA nod for overactive bladder treatment drug
The company has received approval from the USFDA for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | New Drug Applications | Overactive Bladder | Overactive Bladder Syndrome | Pharmaceuticals | VESIcare